TapewireFind a company

person · Reporting owner

Quinn Anthony G.

Disclosed activity across 3 companies

Tapewire entity
67189
SEC CIK
0001532219

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Kaleido Biosciences, Inc.KLDO · Entity 129745DirectorJune 30, 2021July 01, 2021
Spyre Therapeutics, Inc.AGLE · Entity 2649Director · President & CEOMarch 16, 2022March 18, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kaleido Biosciences, Inc.

Report date June 30, 2021 · Filed July 01, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29Direct15,000 Reported balance After 2021-06-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000

Spyre Therapeutics, Inc.

Report date March 16, 2022 · Filed March 18, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect550,540 Reported balance After 2022-03-16 transaction · row 1
1 source row

Row 1 · 2022-03-16 · Purchase · Acquired 80,079 · Balance 550,540

F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Common StockSEC Table I · non-derivativeIndirectBy trusts266,295 Reported balance Holding disclosure · report date 2022-03-16 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 266,295

F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F2: Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Generation Bio Co.

Report date February 09, 2026 · Filed February 09, 2026

Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2026-02-09 transaction · row 1
1 source row

Row 1 · 2026-02-09 · Other · Disposed 29,928 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Common StockSEC Table I · non-derivativeIndirectBy Quinn Family Irrevocable Trust of 20210 Reported balance After 2026-02-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-02-09 · Other · Disposed 7,283 · Balance 0

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87Direct0 Reported balance After 2026-02-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00Direct0 Reported balance After 2026-02-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90Direct0 Reported balance After 2026-02-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90Direct0 Reported balance After 2026-02-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30Direct0 Reported balance After 2026-02-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20Direct0 Reported balance After 2026-02-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.

F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F5: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 6,000 Not disclosed Strike: $33.20 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 8

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 2,500 Not disclosed Strike: $48.30 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 7

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 1,920 Not disclosed Strike: $61.90 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 6

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,920 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 1,500 Not disclosed Strike: $265.90 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 5

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 5,200 Not disclosed Strike: $190.00 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 4

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,200 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 Disposition to issuerStock Option (right to buy) · Derivative 3,000 Not disclosed Strike: $3.87 Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · derivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 OtherCommon Stock 7,283 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Quinn Family Irrevocable Trust of 2021

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3 · ownership.nature: The securities are directly held by the Quinn Family Irrevocable Trust of 2021 (the "Quinn Family Trust"), formerly the Spousal Lifetime Access Trust. Anthony G. Quinn is the settlor of the Quinn Family Trust, M. Clare Quinn is the trustee for the Quinn Family Trust and the Quinn Family Trust is for the benefit of M. Clare Quinn, Emma, Richard, and Charles Quinn.

Read SEC document
February 09, 2026 Filed Feb 9, 2026 17:40 UTC Generation Bio Co. GBIO · Entity 67174 OtherCommon Stock 29,928 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-26-012194 · tm265471-9_4seq1.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Read SEC document
June 04, 2025 Filed Jun 6, 2025 16:05 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $0.39 $0.00
Disclosure

SEC source: 0001415889-25-015958 · form4-06062025_040606.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-03

F1 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders.

Read SEC document
January 13, 2025 Filed Jan 14, 2025 16:05 UTC Generation Bio Co. GBIO · Entity 67174 PurchaseCommon Stock 85,000 $0.97 $82,450.00
Disclosure

SEC source: 0001415889-25-001417 · form4-01142025_040110.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 299,286

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.93 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
January 10, 2025 Filed Jan 14, 2025 16:05 UTC Generation Bio Co. GBIO · Entity 67174 PurchaseCommon Stock 125,791 $0.96 $120,759.36
Disclosure

SEC source: 0001415889-25-001417 · form4-01142025_040110.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,286

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.92 to $0.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 06, 2024 Filed Jun 10, 2024 16:05 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 60,000 $0.00 Strike: $3.32 $0.00
Disclosure

SEC source: 0001415889-24-016184 · form4-06102024_040615.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-06-05

F1 · derivative.exercise_date: This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 16:30 UTC Generation Bio Co. GBIO · Entity 67174 PurchaseCommon Stock 88,495 $1.41 $124,777.95
Disclosure

SEC source: 0001415889-23-015857 · form4-12052023_041204.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,495

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 08, 2023 Filed Jun 12, 2023 16:15 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $4.83 $0.00
Disclosure

SEC source: 0001415889-23-009609 · form4-06122023_040614.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: This option was granted on June 8, 2023. The shares underlying the option will fully vest on the earlier of: June 8, 2024 and the date of Generation Bio's 2024 annual meeting of stockholders.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:05 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 19,200 $0.00 Strike: $6.19 $0.00
Disclosure

SEC source: 0001415889-22-006475 · form4-06132022_040601.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,200

Underlying: Common Stock · 19,200 shares

Expires 2032-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2022. The shares underlying the option will fully vest on the earlier of: June 9, 2023 and the date of Generation Bio's 2023 annual meeting of stockholders.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 06:46 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 80,079 $2.34 $187,705.18
Disclosure

SEC source: 0001209191-22-019929 · doc4.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,540

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Read SEC document
March 15, 2022 Filed Mar 15, 2022 18:32 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 42,417 $1.86 $78,942.28
Disclosure

SEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 473,461

F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.89 to $2.00 per share, inclusive.

Read SEC document
March 14, 2022 Filed Mar 15, 2022 18:32 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 67,472 $1.93 $130,220.96
Disclosure

SEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 431,044

F2 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.93 per share, inclusive.

Read SEC document
March 11, 2022 Filed Mar 15, 2022 18:32 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 34,777 $2.06 $71,779.73
Disclosure

SEC source: 0001209191-22-018942 · doc4.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,572

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.995 to $2.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Read SEC document
February 17, 2022 Filed Feb 22, 2022 16:57 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GrantEmployee Stock Option (right to buy) · Derivative 350,000 $0.00 Strike: $3.17 $0.00
Disclosure

SEC source: 0001209191-22-011724 · doc4.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2032-02-16

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
December 10, 2021 Filed Dec 13, 2021 20:39 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 10,526 $3.75 $39,472.50
Disclosure

SEC source: 0001209191-21-069350 · doc4.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,795

F3 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.62 to $3.80 per share, inclusive.

F2 · balance_after: Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
December 09, 2021 Filed Dec 13, 2021 20:39 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 43,108 $3.70 $159,499.60
Disclosure

SEC source: 0001209191-21-069350 · doc4.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,269

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.

F2 · balance_after: Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
October 28, 2021 Filed Oct 29, 2021 16:01 UTC Generation Bio Co. GBIO · Entity 67174 GiftCommon Stock 72,837 $0.00 $0.00
Disclosure

SEC source: 0001415889-21-005028 · form4-10292021_011020.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 72,837

F1 · kind: The reporting person gifted these shares to the Spousal Lifetime Access Trust (the "Trust").

F2 · ownership.nature: The securities are directly held by the Trust. The reporting person is the settlor of the Trust, M. Clare Quinn is the trustee for the Trust and the Trust is for the benefit of Emma, Richard, and Charles Quinn. The reporting person may be deemed to beneficially own the shares of common stock owned by the Trust.

Read SEC document
October 28, 2021 Filed Oct 29, 2021 16:01 UTC Generation Bio Co. GBIO · Entity 67174 GiftCommon Stock 72,837 $0.00 $0.00
Disclosure

SEC source: 0001415889-21-005028 · form4-10292021_011020.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reporting person gifted these shares to the Spousal Lifetime Access Trust (the "Trust").

Read SEC document
October 20, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 8

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 208,845

F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee.

Read SEC document
October 20, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 7

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,795

Read SEC document
October 18, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 23,809 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 6

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 208,845

F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee.

Read SEC document
October 18, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 23,809 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 5

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,795

Read SEC document
October 14, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 175,036 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 4

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 208,845

F2 · ownership.nature: These securities are held by the Quinn Family Irrevocable Trust of 2021, of which the Reporting Person's spouse is trustee.

Read SEC document
October 14, 2021 Filed Feb 14, 2022 17:19 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GiftCommon Stock 175,036 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-009407 · doc5.xml · nonDerivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,795

Read SEC document
June 30, 2021 Filed Jul 1, 2021 16:22 UTC Kaleido Biosciences, Inc. KLDO · Entity 129745 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $7.44 $0.00
Disclosure

SEC source: 0001209191-21-044388 · doc4.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-29

Read SEC document
June 09, 2021 Filed Jun 11, 2021 16:08 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $26.59 $0.00
Disclosure

SEC source: 0001415889-21-002949 · form4-06112021_010609.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021. The shares underlying the option will fully vest on the earlier of: June 9, 2022 and the date of Generation Bio's 2022 annual meeting of stockholders.

Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:08 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GrantEmployee Stock Option (right to buy) · Derivative 330,000 $0.00 Strike: $7.35 $0.00
Disclosure

SEC source: 0001209191-21-012424 · doc4.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,000

Underlying: Common Stock · 330,000 shares

Expires 2031-02-16

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2021, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
June 30, 2020 Filed Jul 1, 2020 16:16 UTC Kaleido Biosciences, Inc. KLDO · Entity 129745 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $7.43 $0.00
Disclosure

SEC source: 0001209191-20-039724 · doc4.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-30

Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:31 UTC Generation Bio Co. GBIO · Entity 67174 ConversionSeries C Preferred Stock · Derivative 53,654 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-017107 · doc4.xml · derivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,376 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.exercise_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.expiration_date: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Read SEC document
June 16, 2020 Filed Jun 18, 2020 17:31 UTC Generation Bio Co. GBIO · Entity 67174 ConversionCommon Stock 30,376 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-017107 · doc4.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On June 16, 2020, the Series C Preferred Stock automatically converted into Common Stock on a 1.7663-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Read SEC document
June 11, 2020 Filed Jun 15, 2020 17:23 UTC Generation Bio Co. GBIO · Entity 67174 GrantStock Option (right to buy) · Derivative 52,000 $0.00 Strike: $19.00 $0.00
Disclosure

SEC source: 0000899243-20-016553 · doc4.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on June 11, 2021 and the remaining shares vesting in equal quarterly installments thereafter.

Read SEC document
April 30, 2020 Filed May 4, 2020 07:30 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 165,000 $4.75 $783,750.00
Disclosure

SEC source: 0001209191-20-026662 · doc4.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 538,469

F1 · balance_after: Includes 788 shares acquired by the Reporting Person on August 15, 2019 and 773 shares acquired by the Reporting Person on February 15, 2020 pursuant to the Issuer's employee stock purchase plan.

Read SEC document
February 14, 2020 Filed Feb 19, 2020 17:13 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 GrantEmployee Stock Option (right to buy) · Derivative 301,000 $0.00 Strike: $8.15 $0.00
Disclosure

SEC source: 0001567619-20-004316 · doc1.xml · derivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 301,000

Underlying: Common Stock · 301,000 shares

Expires 2030-02-13

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 14, 2020, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
October 04, 2019 Filed Oct 7, 2019 16:09 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 Exercise / conversionStock Option (right to buy) · Derivative 17,603 $0.00 Strike: $6.31 $0.00
Disclosure

SEC source: 0001567619-19-019297 · doc1.xml · derivative · entry 4

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,914

Underlying: Common Stock · 17,603 shares

Expires 2028-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vests and becomes exerciseable in 48 equal monthly installments beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Read SEC document
October 04, 2019 Filed Oct 7, 2019 16:09 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 Exercise / conversionStock Option (right to buy) · Derivative 662 $0.00 Strike: $5.46 $0.00
Disclosure

SEC source: 0001567619-19-019297 · doc1.xml · derivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 662 shares

Expires 2026-03-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested and became exerciseable as to 1/36th of the shares subject to the option on April 3, 2016, and thereafter vests as to 1/36th of the shares each month in equal installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document
October 04, 2019 Filed Oct 7, 2019 16:09 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 Exercise / conversionCommon Stock 17,603 $6.31 $111,074.93
Disclosure

SEC source: 0001567619-19-019297 · doc1.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 371,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 04, 2019 Filed Oct 7, 2019 16:09 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 Exercise / conversionCommon Stock 662 $5.46 $3,614.52
Disclosure

SEC source: 0001567619-19-019297 · doc1.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 14, 2019 Filed Jun 14, 2019 17:22 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 5,282 $6.23 $32,912.67
Disclosure

SEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,643

F3 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.18 to $6.2825 per share.

Read SEC document
June 13, 2019 Filed Jun 14, 2019 17:22 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 14,406 $6.17 $88,836.04
Disclosure

SEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,361

F2 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.14 to $6.23 per share.

Read SEC document
June 12, 2019 Filed Jun 14, 2019 17:22 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 12,217 $6.11 $74,704.51
Disclosure

SEC source: 0001567619-19-013411 · doc1.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,955

F1 · price: Represents the weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.07 to $6.20 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

Read SEC document
May 22, 2019 Filed May 22, 2019 16:55 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 3,809 $6.86 $26,128.22
Disclosure

SEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 3

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,738

F3 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.69 to $7.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
May 21, 2019 Filed May 22, 2019 16:55 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 13,794 $6.89 $94,981.35
Disclosure

SEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 2

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,929

F2 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.53 to $7.00 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
May 20, 2019 Filed May 22, 2019 16:55 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 8,989 $6.56 $58,922.90
Disclosure

SEC source: 0001567619-19-011852 · doc1.xml · nonDerivative · entry 1

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 304,135

F1 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.39 to $6.73 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document
May 17, 2019 Filed May 17, 2019 17:04 UTC Spyre Therapeutics, Inc. AGLE · Entity 2649 PurchaseCommon Stock 6,218 $6.65 $41,335.40
Disclosure

SEC source: 0001567619-19-011561 · doc1.xml · nonDerivative · entry 4

Quinn Anthony G. · CIK 0001532219 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,146

F4 · price: Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $6.51 to $6.85 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.